{"DataElement":{"publicId":"5810385","version":"1","preferredName":"Anthracycline Antineoplastic Antibiotic Administered Type","preferredDefinition":"A description of the anthracyclines that were administered.","longName":"5810384v1.0:2750844v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5810384","version":"1","preferredName":"Anthracycline Antineoplastic Antibiotic Administered","preferredDefinition":"An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction._The act of having given something (e.g., a medication or test).","longName":"5810382v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5810382","version":"1","preferredName":"Anthracycline Antineoplastic Antibiotic","preferredDefinition":"A type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.","longName":"C1594","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anthracycline Antineoplastic Antibiotic","conceptCode":"C1594","definition":"An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EF419EA-8BDA-1ADA-E053-F662850AEDE7","latestVersionIndicator":"Yes","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EF419EA-8BE8-1ADA-E053-F662850AEDE7","latestVersionIndicator":"Yes","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"NYCHM","dateModified":"2017-08-28","changeDescription":".released 8/28/17.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2750844","version":"1","preferredName":"Anthracycline Antineoplastic Antibiotic Type","preferredDefinition":"Antineoplastic antibiotics isolated from the bacterium Streptococcus peucetius var. caesius or derived synthetically.  Anthracycline antibiotics exhibit potent cytotoxic properties due to their ability to intercalate into DNA and interact with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  These agents also produce toxic free-radical intermediates and interact with cell membrane lipids, causing lipid peroxidation. (NCI04)_Type; a subdivision of a particular kind of thing.","longName":"ANTH_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Anthracycline","valueDescription":"Anthracycline Antibiotic","ValueMeaning":{"publicId":"2750845","version":"1","preferredName":"Anthracycline Antibiotic","longName":"2750845","preferredDefinition":"A member of a family of anticancer drugs that are also antibiotics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anthracycline Antineoplastic Antibiotic","conceptCode":"C1594","definition":"An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D9A553A-6F0D-6A30-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D9A553A-6F26-6A30-E044-0003BA3F9857","beginDate":"2008-05-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-19","modifiedBy":"ALEYR","dateModified":"2008-05-19","deletedIndicator":"No"},{"value":"Daunorubicin","valueDescription":"Daunorubicin","ValueMeaning":{"publicId":"2724326","version":"1","preferredName":"Daunorubicin","longName":"2724326","preferredDefinition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daunorubicin","conceptCode":"C62091","definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FAAF5-415D-370B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D9A553A-6F32-6A30-E044-0003BA3F9857","beginDate":"2008-05-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-19","modifiedBy":"ALEYR","dateModified":"2008-05-19","deletedIndicator":"No"},{"value":"Doxorubicin","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2744954","version":"1","preferredName":"Doxorubicin","longName":"2744954","preferredDefinition":"An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-8077-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D9A553A-6F47-6A30-E044-0003BA3F9857","beginDate":"2008-05-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-19","modifiedBy":"ALEYR","dateModified":"2008-05-19","deletedIndicator":"No"},{"value":"Idarubicin","valueDescription":"Idarubicin","ValueMeaning":{"publicId":"2744955","version":"1","preferredName":"Idarubicin","longName":"2744955","preferredDefinition":"A semisynthetic anthracycline antineoplastic antibiotic derived from daunorubicin.  Idarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes better than other anthracycline antibiotics.  Idarubicin hydrochloride is the therapeutic form of this drug. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idarubicin","conceptCode":"C562","definition":"A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-80C8-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D9A553A-6F5C-6A30-E044-0003BA3F9857","beginDate":"2008-05-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-19","modifiedBy":"ALEYR","dateModified":"2008-05-19","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A1CFE6-3EB1-FAB4-E040-BB89AD432494","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"Rubidazone","valueDescription":"Zorubicin","ValueMeaning":{"publicId":"2829936","version":"1","preferredName":"Zorubicin","longName":"2829936","preferredDefinition":"A benzoyl-hydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin.  Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zorubicin Hydrochloride","conceptCode":"C1458","definition":"A benzoyl-hydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin.  Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"618DC679-B0DB-32DD-E040-BB89AD43461A","latestVersionIndicator":"Yes","beginDate":"2009-01-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A1CFE6-3EC5-FAB4-E040-BB89AD432494","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"Liposomal Doxorubicin","valueDescription":"Liposomal Doxorubicin Regimen","ValueMeaning":{"publicId":"7652417","version":"1","preferredName":"Liposomal Doxorubicin Regimen","longName":"7652417","preferredDefinition":"A chemotherapy regimen consisting of liposomal doxorubicin that may be used in the treatment of desmoid tumors (aggressive fibromatoses); soft tissue, uterine, and AIDS-related Kaposi sarcomas; and ovarian, fallopian tube, primary peritoneal, breast, and endometrial cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Doxorubicin Regimen","conceptCode":"C160080","definition":"A regimen consisting of liposomal doxorubicin that may be used in the treatment of desmoid tumors (aggressive fibromatoses); soft tissue, uterine, and Kaposi sarcomas; mycosis fungoides and Sezary syndrome; Castleman disease; and ovarian, fallopian tube, primary peritoneal, breast, and endometrial cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1AB183A-4A61-71FF-E053-4EBD850A884B","latestVersionIndicator":"Yes","beginDate":"2021-05-06","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-05-06","modifiedBy":"MAESKEB","dateModified":"2021-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1AB183A-4A7A-71FF-E053-4EBD850A884B","beginDate":"2021-05-06","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-05-06","modifiedBy":"ONEDATA","dateModified":"2021-05-06","deletedIndicator":"No"},{"value":"Amsacrine","valueDescription":"Amsacrine","ValueMeaning":{"publicId":"6159871","version":"1","preferredName":"Amsacrine","longName":"6159871","preferredDefinition":"An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amsacrine","conceptCode":"C240","definition":"An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AC3EB1-CC12-43A6-E053-F662850AD41E","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1AB183A-4A8E-71FF-E053-4EBD850A884B","beginDate":"2021-05-06","endDate":null,"createdBy":"ZHANGW","dateCreated":"2021-05-06","modifiedBy":"ONEDATA","dateModified":"2021-05-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2750843","version":"1","preferredName":"Anthracycline Antibiotic Type","preferredDefinition":"A member of a family of anticancer drugs that are also antibiotics.:Type; a subdivision of a particular kind of thing.","longName":"C1594:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anthracycline Antineoplastic Antibiotic","conceptCode":"C1594","definition":"An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D9A553A-6EE5-6A30-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-19","modifiedBy":"ONEDATA","dateModified":"2008-05-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D9A553A-6EF6-6A30-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-19","modifiedBy":"MAESKEB","dateModified":"2021-05-07","changeDescription":". 11/5/09mn-added 2 pv - rubidazone (zorubicin hydrochloride C1458) and other for F2000. 5/6/21wz: approved and added PVs Liposomal doxorubicin and Amsacrine for external request.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685478","version":"1","longName":"Testing Set – Moderately Different","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedSubstanceAdministration:negationIndicator","type":"HCT_BRIDG_5","context":"NHLBI"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"DG_ABX_ADMR_TP","type":"COG GDE Short Name","context":"COG"}],"ReferenceDocuments":[{"name":"What was the type of anthracycline administered?","type":"Alternate Question Text","description":"What was the type of anthracycline administered?","url":null,"context":"NHLBI"},{"name":"What were the anthracyclines","type":"Preferred Question Text","description":"What were the anthracyclines that were administered?","url":null,"context":"NHLBI"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Other anthracycline:","url":null,"context":"COG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EF419EA-8C01-1ADA-E053-F662850AEDE7","latestVersionIndicator":"Yes","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"BROWNTY","dateModified":"2021-05-05","changeDescription":"System generated de displayed as alt def. released 8/28/17;Added HCT_BRIDG5 alternate name - RR 2018-12-21","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}